Forte Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 9
- Market Cap
- -
- Website
- http://www.fortebiorx.com
- Introduction
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner in 2017 and is headquartered in Dallas, TX.
FibroBiologics Partners with Charles River to Advance Fibroblast-Based Therapy for Diabetic Foot Ulcers
• FibroBiologics has completed a proprietary master cell bank for its fibroblast-based therapy CYWC628, which targets diabetic foot ulcers affecting millions worldwide.
• The company has established a partnership with Charles River Laboratories to manufacture the cell bank and drug products for an upcoming Phase I/II clinical trial scheduled to begin in Q2 2025 in Australia.
• With $14 million in cash reserves and access to additional financing, FibroBiologics aims to complete the clinical trial by the end of 2025, potentially revolutionizing treatment for chronic wounds.
Renewed Hope for Glioblastoma: Novel Therapies Show Promise After Decades of Stagnation
• New therapeutic approaches, including small molecules, cell therapies, and vaccines, are revitalizing glioblastoma research after 20 years of limited progress.
• Merck's acquisition of Modifi Biosciences and Kazia Therapeutics' paxalisib are leading the charge with innovative small molecule therapies targeting DNA repair and PI3K pathways, respectively.
• CAR T-cell therapies targeting EGFR and interleukin-13 receptor alpha 2, along with vaccines like SurVaxM, are showing early promise in shrinking tumors and improving survival.
• The glioblastoma market is projected to grow to $5.7 billion by 2033, driven by targeted therapies and immunotherapies, signaling increased investment and innovation in the field.
© Copyright 2025. All Rights Reserved by MedPath